Merck & Company Inc (MRK)vsEntrada Therapeutics Inc (TRDA)
MRK
Merck & Company Inc
$109.18
+2.73%
HEALTHCARE · Cap: $274.03B
TRDA
Entrada Therapeutics Inc
$14.50
+7.41%
HEALTHCARE · Cap: $503.12M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 255637% more annual revenue ($65.01B vs $25.42M). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
TRDA
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-16.2%
Fair Value
$96.56
Current Price
$109.18
$12.62 premium
Intrinsic value data unavailable for TRDA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : TRDA
The strongest argument for TRDA centers on Debt/Equity, Price/Book.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : TRDA
The primary concerns for TRDA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK carries more volatility with a beta of 0.28 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 28/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Entrada Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Entrada Therapeutics Inc. (TRDA) is an innovative biotechnology company dedicated to developing groundbreaking therapies to address severe diseases with significant unmet medical needs. Utilizing its proprietary Therapeutics for RNA Delivery (TRADA) platform, Entrada targets RNA and protein dysfunctions linked to conditions such as muscular dystrophies and genetic disorders. The firm boasts a strong clinical pipeline and a commitment to scientific excellence, positioning itself well for impactful advancements in patient care. Led by an experienced team, Entrada is poised to make significant contributions to the biopharmaceutical industry through its cutting-edge therapeutic solutions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?